We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Kimberly-Clark (KMB) Up 0.2% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Kimberly-Clark (KMB - Free Report) . Shares have added about 0.2% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Kimberly-Clark due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Kimberly-Clark reported third-quarter 2019 results, wherein adjusted earnings of $1.84 per share surpassed the Zacks Consensus Estimate of $1.80 and increased 7.6% from the year-ago period. The solid performance was also followed by a raised earnings outlook for the year.
Management now envisions 2019 earnings of $6.75-$6.90 per share, up from the prior forecast of $6.65-$6.80.
Quarter in Detail
Kimberly-Clark’s sales came in at $4,640 million, which fell short of the Zacks Consensus Estimate of $4,647 million. However, the top line climbed 1% year over year. Unfavorable currency movements weighed on sales by 2%. Also, business exits pertaining to the 2018 Global Restructuring Program had a slight negative impact on sales.
Organic sales rose 4% year over year, owing to improved net selling prices (up 4%) and product mix (up 1%), somewhat offset by a 1% drop in volumes.
In North America, organic sales in consumer products and K-C Professional rose 4% and 5%, respectively. Internationally, organic sales increased 5% across developing and emerging markets, while it grew 1% in developed markets.
Adjusted operating profit came in at $859 million, up from $798 million in the year-ago quarter. Results gained from higher net selling prices along with cost savings of $50 million and $45 million from FORCE (Focused On Reducing Costs Everywhere) program and 2018 Global Restructuring Program, respectively.
Further, lower input costs stemming from a decline in raw material expenses benefited results.
However, unfavorable currency translations, higher manufacturing costs, increased advertising expenses and a rise in general and administrative costs negatively impacted adjusted operating profit.
Segment Details
Personal Care Products: Segment sales of $2,305 million rose roughly 2%, owing to improved net selling prices (up 3%), volumes (up 1%) and product mix (up 1%). This, to an extent, was offset by unfavorable currency rates, which hurt sales by 3%. Further, sales increased 5% in North America and 3% in developing and emerging markets. Sales declined 3% across developed markets outside North America.
Consumer Tissue: Segment sales of $1,484 million grew about 1% year over year. Results gained from improved net selling prices (up 5%), partially offset by lower volumes (down 2%). Adverse currency movements hurt sales by 2%. Sales grew 3% in North America and 1% in developing and emerging markets. Sales dropped 4% across developed markets outside North America.
K-C Professional (KCP): Segment sales dropped 1% to $839 million due to a 2% impact each from adverse currency rates and several business exits as part of the 2018 Global Restructuring Plan. Volumes were down 2%. This was somewhat cushioned by improved product mix (up 1%) and higher net selling prices (up 3%). Sales rose 4% in North America, while the same declined 2% and 7% in developing and emerging markets, and developed markets outside North America, respectively.
Other Financial Updates
The company ended the quarter with cash and cash equivalents of $416 million, long-term debt of $6,198 million and stockholders' deficit of $141 million, excluding non-controlling interest of $229 million.
Further, Kimberly-Clark generated cash flow of $886 million from operating activities during the quarter under review. Management incurred capital expenditures of $298 million. During the quarter, Kimberly-Clark returned roughly $570 million to shareholders via dividends payouts and share buybacks. To this end, the company bought back 1.6 million shares for approximately $214 million. For 2019, management expects share buybacks of $800 million.
Other Developments & Guidance
Management is on track with the 2018 Global Restructuring Program, which is aimed at lowering the company’s structural costs and improving financial flexibility. Until the third quarter of 2019, Kimberly-Clark incurred pre-tax cumulative restructuring charges of $1,251 million related to this program, while it made cumulative savings worth $260 million from the same.
Management now forecasts full-year net sales to drop year over year. The company had earlier expected net sales to be flat to down 1% year over year. Kimberly-Clark now projects organic sales improvement of 3-4% compared with prior guidance of 3% growth.
Management anticipates adjusted operating profit growth of 4-5% for the year. Earlier, the company estimated 3-5% growth.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
At this time, Kimberly-Clark has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Kimberly-Clark has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Kimberly-Clark (KMB) Up 0.2% Since Last Earnings Report?
It has been about a month since the last earnings report for Kimberly-Clark (KMB - Free Report) . Shares have added about 0.2% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Kimberly-Clark due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Kimberly-Clark Q3 Earnings Beat, Organic Sales Improve
Kimberly-Clark reported third-quarter 2019 results, wherein adjusted earnings of $1.84 per share surpassed the Zacks Consensus Estimate of $1.80 and increased 7.6% from the year-ago period. The solid performance was also followed by a raised earnings outlook for the year.
Management now envisions 2019 earnings of $6.75-$6.90 per share, up from the prior forecast of $6.65-$6.80.
Quarter in Detail
Kimberly-Clark’s sales came in at $4,640 million, which fell short of the Zacks Consensus Estimate of $4,647 million. However, the top line climbed 1% year over year. Unfavorable currency movements weighed on sales by 2%. Also, business exits pertaining to the 2018 Global Restructuring Program had a slight negative impact on sales.
Organic sales rose 4% year over year, owing to improved net selling prices (up 4%) and product mix (up 1%), somewhat offset by a 1% drop in volumes.
In North America, organic sales in consumer products and K-C Professional rose 4% and 5%, respectively. Internationally, organic sales increased 5% across developing and emerging markets, while it grew 1% in developed markets.
Adjusted operating profit came in at $859 million, up from $798 million in the year-ago quarter. Results gained from higher net selling prices along with cost savings of $50 million and $45 million from FORCE (Focused On Reducing Costs Everywhere) program and 2018 Global Restructuring Program, respectively.
Further, lower input costs stemming from a decline in raw material expenses benefited results.
However, unfavorable currency translations, higher manufacturing costs, increased advertising expenses and a rise in general and administrative costs negatively impacted adjusted operating profit.
Segment Details
Personal Care Products: Segment sales of $2,305 million rose roughly 2%, owing to improved net selling prices (up 3%), volumes (up 1%) and product mix (up 1%). This, to an extent, was offset by unfavorable currency rates, which hurt sales by 3%. Further, sales increased 5% in North America and 3% in developing and emerging markets. Sales declined 3% across developed markets outside North America.
Consumer Tissue: Segment sales of $1,484 million grew about 1% year over year. Results gained from improved net selling prices (up 5%), partially offset by lower volumes (down 2%). Adverse currency movements hurt sales by 2%. Sales grew 3% in North America and 1% in developing and emerging markets. Sales dropped 4% across developed markets outside North America.
K-C Professional (KCP): Segment sales dropped 1% to $839 million due to a 2% impact each from adverse currency rates and several business exits as part of the 2018 Global Restructuring Plan. Volumes were down 2%. This was somewhat cushioned by improved product mix (up 1%) and higher net selling prices (up 3%). Sales rose 4% in North America, while the same declined 2% and 7% in developing and emerging markets, and developed markets outside North America, respectively.
Other Financial Updates
The company ended the quarter with cash and cash equivalents of $416 million, long-term debt of $6,198 million and stockholders' deficit of $141 million, excluding non-controlling interest of $229 million.
Further, Kimberly-Clark generated cash flow of $886 million from operating activities during the quarter under review. Management incurred capital expenditures of $298 million. During the quarter, Kimberly-Clark returned roughly $570 million to shareholders via dividends payouts and share buybacks. To this end, the company bought back 1.6 million shares for approximately $214 million. For 2019, management expects share buybacks of $800 million.
Other Developments & Guidance
Management is on track with the 2018 Global Restructuring Program, which is aimed at lowering the company’s structural costs and improving financial flexibility. Until the third quarter of 2019, Kimberly-Clark incurred pre-tax cumulative restructuring charges of $1,251 million related to this program, while it made cumulative savings worth $260 million from the same.
Management now forecasts full-year net sales to drop year over year. The company had earlier expected net sales to be flat to down 1% year over year. Kimberly-Clark now projects organic sales improvement of 3-4% compared with prior guidance of 3% growth.
Management anticipates adjusted operating profit growth of 4-5% for the year. Earlier, the company estimated 3-5% growth.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
At this time, Kimberly-Clark has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Kimberly-Clark has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.